Aroa Biosurgery's (ASX:ARX) secured regulatory approvals to market and sell the Endoform and Myriad Matrix products in Argentina and Endoform in Egypt, according to a Tuesday filing with the Australian bourse.
Endoform was developed for the management of acute and chronic wounds, while Myriad Matrix is used in soft tissue reconstruction and complex wounds.
The soft tissue regeneration firm's cash receipts rose 35% to NZ$19.9 million in the second quarter ended Sept. 30, compared with the previous comparable period, the filing added.
Shares of Aroa Biosurgery rallied almost 12% at market close.
Price (AUD): $0.58, Change: $+0.060, Percent Change: +11.54%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。